B
BCAX

Braidwell’s Bicara Therapeutics BCAX Stock Holding History

Braidwell’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,162,803
Closed -$28.2M – 65
2025
Q1 		$28.2M Buy
2,162,803
+162,144
+8% +$2.15M 0.99% 37
2024
Q4 		$34.9M Buy
2,000,659
+343,059
+21% +$7.14M 1.03% 39
2024
Q3 		$42.2M Buy
+1,657,600
New +$42.3M 1.2% 35

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell's BCAX Position: Q2 2025 in Review

Braidwell sold out of Bicara Therapeutics (BCAX) in Q2 2025, closing a stake of 2,162,803 shares — an estimated $28.2M sold.

Braidwell first reported a position in BCAX in Q3 2024 and held it in 3 quarters. The position peaked at $42.2M in Q3 2024. 106 funds tracked by Wall St. Rank hold BCAX as of Q2 2025.

  • Braidwell reported no remaining Bicara Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Braidwell sold 2,162,803 Bicara Therapeutics shares in Q2 2025, an estimated $28.2M.
  • Braidwell first reported a position in Bicara Therapeutics in Q3 2024 and held it in 3 quarters.
  • Braidwell's Bicara Therapeutics position peaked at $42.2M in Q3 2024.
  • 106 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.